A case of irreversible alopecia associated with ribavirin and peg-interferon therapy

Shafa, Shervin; Borum, Marie; Igiehon, Enaruna

doi:10.1097/meg.0b013e32832be7a5

Cited by 16 publications

(7 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consequently, AU was defined as a rare and reversible side‐effect of PEG IFN–ribavirin treatment and it was not considered an indication to stop therapy in patients who respond to drugs. Recently, a case of irreversible alopecia totalis associated with PEG IFN–ribavirin was reported (Table 1), 21 and for the first time we report a case of refractory AU during PEG IFN treatment. Taken together, these reports suggest that alopecia could be a severe and permanent side‐effect of PEG IFN treatment.…”

Section: Discussionmentioning

confidence: 66%

Irreversible alopecia universalis during treatment with pegylated interferon–ribavirin for chronic hepatitis C virus infection: Case report and published work review

Omazzi¹,

Prada²,

Borroni³

et al. 2012

Hepatology Research

View full text Add to dashboard Cite

Hair disorders that have been described in association with pegylated interferon-ribavirin combination treatment include canities, hypertrichosis, telogen effluvium, and the most common cutaneous side-effect by far, alopecia. Alopecia is a heterogeneous disease characterized by hair loss on the scalp or any hair-bearing surface with a wide range of clinical presentations, from a single patch of hair loss to complete loss of hair on the entire body (alopecia universalis). Although some cases of reversible alopecia universalis associated with pegylated interferon-ribavirin combination therapy have been reported in the published work, irreversible alopecia universalis has not yet been reported in relation to pegylated interferon and ribavirin combination treatment. For the first time, we report a case of irreversible alopecia universalis during pegylated interferon-ribavirin combination therapy in a man infected with hepatitis C virus in the absence of clinical or biochemical evidence of immunological disorders or thyroid dysfunction at any time before, during or after antiviral therapy.

show abstract

Section: Discussionmentioning

confidence: 66%

Irreversible alopecia universalis during treatment with pegylated interferon–ribavirin for chronic hepatitis C virus infection: Case report and published work review

Omazzi¹,

Prada²,

Borroni³

et al. 2012

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…İmmün sistemin aktivasyonuyla birlikte kıl bulbusunun çevresinde CD4+, CD8+ T hücrelerden ve NK hücrelerden oluşan otoreaktif lenfositik infiltrasyon gelişir ve kıl follikülünde apoptotik süreç tetiklenir. İlaç kullanımı ile alopesi areata gelişimi arasındaki ilişki tam olarak açıklığa kavuşturulmuş olmamasına karşın, adalimumab, infliksimab, etanersept, leflunomid, ve interferon gibi immün sistemi etkileyen ilaçların alopesi areata oluşumuna neden olduğu rapor edilmiştir [8][9][10][11][12] . Alopesi areata lezyonlarında IFN-γ, IL-2, TNF-α, CXCL9 ve CXCL10 ekspresyonunda artış izlenmektedir 9 .…”

Section: Discussionunclassified

A case of lenflunomide-induced alopecia areata

Açıkgöz¹,

Yeniay²,

Çalışkan³

et al. 2015

TURKDERM

View full text Add to dashboard Cite

Leflunomide is an immunomodulatory drug widely used in the treatment of inflammatory arthritis, especially in rheumatoid arthritis and psoriatic arthritis. The common side effects of leflunomide are hepatopathy, hypertension, various gastrointestinal complaints and transient hair loss, which are all mild and reversible. Although leflunomide is associated with transient hair loss, only one case of leflunomide-induced alopecia areata has been reported previously. In this case report, we present a 38-year-old male patient who suffered from alopecia areata after leflunomide therapy. (Turkderm 2015; 49: 78-80)

show abstract

“…[14][15][16][17][18][19][20][21][22][23][24][25][26][27] The pathogenesis of alopecia areata in patients taking anti-TNF-a medications is thought to be caused by the development of autoimmunity as a result of taking the drug. 28,29 The mechanism of the pathogenesis of vandetanib-related alopecia areata remains to be elucidated.…”

Section: Discussionmentioning

confidence: 99%

Vandetanib‐associated alopecia areata in a patient with metastatic medullary thyroid cancer

Jalalat

Cohen

2014

Int J Dermatology

View full text Add to dashboard Cite

A case of irreversible alopecia associated with ribavirin and peg-interferon therapy

Cited by 16 publications

References 2 publications

Irreversible alopecia universalis during treatment with pegylated interferon–ribavirin for chronic hepatitis C virus infection: Case report and published work review

Irreversible alopecia universalis during treatment with pegylated interferon–ribavirin for chronic hepatitis C virus infection: Case report and published work review

A case of lenflunomide-induced alopecia areata

Vandetanib‐associated alopecia areata in a patient with metastatic medullary thyroid cancer

Contact Info

Product

Resources

About